Lb Pharmaceuticals (LBRX) Consolidated Net Income (2024 - 2026)

Lb Pharmaceuticals' Consolidated Net Income history runs 3 years deep, the most recent figure standing at -$19.1 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 259.1% year-over-year to -$19.1 million; the TTM figure through Mar 2026 stood at -$39.4 million (changed N/A YoY), while the FY2025 annual figure was -$25.2 million, up 60.06% from the prior year.
• Consolidated Net Income was -$19.1 million for Q1 2026 at Lb Pharmaceuticals, down from -$11.5 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$3.6 million in Q3 2025 to a low of -$19.1 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$9.8 million across 3 years, with a median of -$8.4 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Consolidated Net Income jumped 74.92% in 2025, then slumped 259.1% in 2026.
• A 3-year view of Consolidated Net Income shows it stood at -$5.1 million in 2024, then plunged by 126.23% to -$11.5 million in 2025, then tumbled by 66.09% to -$19.1 million in 2026.
• The last three Consolidated Net Income figures came in at -$19.1 million (Q1 2026), -$11.5 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.